Current therapy and nutraceuticals for the treatment of patients with dyslipidemias.

Current therapy and nutraceuticals for the treatment of patients with dyslipidemias. Curr Pharm Des. 2019 Jan 29;: Authors: Scognamiglio M, Costa D, Sorriento A, Napoli C Abstract Coronary heart disease (CHD) remain the leading cause of disability and death in industrialized Countries. Among many conditions that contribute to the etiology and progression of CHD, the presence of high LDL-C levels represent the major risk factor. Therefore, the reduction of LDL-C levels play a key role in the management of patients with high or very high cardiovascular risk. Although statins represent the gold standard therapy for the reduction of cholesterol levels, do not allow to achieve target levels of LDL-C in all patients. Indeed, a significant number of patients result statin-intolerants, especially when the dosage increase. The availability of new lipid-lowering drugs such as ezetimibe and PCSK9 inhibitors may represent an important alternative or complement to the conventional lipid-lowering therapies. However, long-term studies are still needed to define efficacy and safety of use of these latter new drugs. Some nutraceuticals may became an adequate and effective support in the management of some patients. To date, several nutraceuticals with different mechanism of actions that provide a good tolerability are available as lipid-lowering agents. In particular, the most investigated are red yeast rice, phytosterols, berberine, beta-glucans and...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research